Centauri Team Building Day at Jodrell Bank
We enjoyed a Company Team Day at Jodrell Bank in August. During the day, our CEO Jen reflected on Centauri’s significant achievements over the past 18 months and our plans for the coming year. We also explored and discussed our company values. We were lucky to have some down…
Race For Life 2023
Centauri Therapeutics Fundraising Team really enjoyed their first event ‘Race For Life 2023’. Pam, our Head of Chemistry, kicked off the event, with her race…
BIA Life Sciences Leadership Summit
On 19- 20 June, our CEO Jen, and VP of R&D Helen, were delighted to be part of the BioIndustry Association’s recent Life Sciences Leadership Summit…
150 Years of Infectious Disease Research and Innovation
We are proud of our Project Manager, Rinki Deb, who spoke at the 2048 – 150 Years of Infectious Disease Research and Innovation event on…
Earth Day 2023
As part of Earth Day on 22 April and the theme ‘Invest in our Planet’, we joined colleagues at Alderley Park to plant a tree and make…
Centauri Therapeutics attended ID Week 2022
Jennifer Schneider, CEO and Helen Bright, VP of Research & Development at Centauri Therapeutics, attended ID Week 2022, which took place from 19th to 23rd…
Centauri Therapeutics Dr Mike Westby attended ESCMID/ASM Conference 2022
Dublin, 4th to 7th October 2022 – Dr Mike Westby, Centauri’s Chief Scientific Officer, presented at the 2022 ESCMID/ASM Conference on Drug Development, which aims to…
Centauri welcomes Alison Gallop
Centauri is pleased to welcome Alison Gallop to the team as Office Manager. Alison has many years of experience in office management and finance.
Centauri story featured in Sunday Times
Centauri's story through an interview with CSO Dr Mike Westby was featured in a Sunday Times article written by Sabah Meddings.
Centauri awarded follow-on CARB-X grant
Centauri Therapeutics Limited, an immunotherapy company focused on the treatment of infectious diseases, has been awarded a grant of up to $2.7 million USD (c.£2…
Centauri Therapeutics closes £24m Series A investment round
Centauri Therapeutics is delighted to announce new investment of £24m in antimicrobial research and appointment of new company directors. See attached press release